Five Yale researchers awarded grants to study women’s reproductive cancers
Five researchers from the Yale School of Medicine have received grants from Discovery to Cure, a program at the Department of Obstetrics, Gynecology, and Reproductive Sciences that advances the prevention, early detection, and treatment of women’s reproductive cancers such as ovarian, uterine, cervical, vaginal, and vulvar cancers.
PFAS and Phenols Linked to Different Cancers in Women of Different Races
A new federally-funded study in the Journal of Exposure Science & Environmental Epidemiology has found that compounds called phenols, and the synthetic chemicals PFAS, were linked to different kinds of cancer in white women and women of color. PFAS were linked to ovarian and uterine cancers mainly in white women, and phenols were linked more to breast cancer in non-white women. Phenols and PFAS are found in hundreds of daily consumer products. The researchers stated that the racial differences are particularly impactful because of racial disparities in exposure to these chemicals. Nicole Deziel, member of the Yale Cancer Center and associate professor of epidemiology (environmental sciences) at Yale School of Public Health, who is not associated with the study, said the findings “provided a lot of new information suggesting that exposure to PFAS could be associated with a variety of hormonally related cancers, particularly in women.”Source: CT Public Radio
AI More Accurately Identifies Patients With Advanced Lung Cancer Who Respond to Immunotherapy
Researchers compared AI-powered digital scoring with traditional manual scoring of the PD-L1 immune biomarker to determine if a new immunotherapy treatment, atezolizumab, could benefit patients with advanced non-small cell lung cancer.
Breakthrough Targeted Therapy Approach for Non-Small Cell Lung Cancer Helps Patients With a Genetic Mutation Live Longer
Yale Cancer Center researchers at Yale School of Medicine discovered that patients with stage III NSCLC and an EGFR genetic mutation had improved survival outcomes with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) after being treated with chemoradiation.
Engaging People with Low-Grade Glioma in Cancer Research
Some people with low-grade glioma, a type of brain tumor, can live for years, even decades, without the disease worsening. But eventually these cancers start to grow, and little is known about why—or how—this happens. An NCI-supported study called OPTIMUMExit Disclaimer (Optimizing Engagement in Discovery of Molecular Evolution of Low-Grade Glioma) could provide some answers.Source: National Cancer Institute
Research reveals boosting strategies that mitigate risks of COVID-19 in cancer patients
New research led by scientists at Yale University and the University of North Carolina at Charlotte finds that the rate at which additional COVID-19 boosters are needed for cancer patients depends on the treatment they are receiving.
Lessons from KEYNOTE-921 in Metastatic Castration Resistant Prostate Cancer
Clinical trials around the world continue to evaluate and bring promising new treatments to patients with various types of genitourinary cancers. However, not all are positive, according to Daniel P. Petrylak, MD, including the phase 3 KEYNOTE-921 study (NCT03834506).Source: Targeted Oncology
Study: Breast Cancer Screening May Not Be as Helpful for Older Women
Breast cancer screenings past the age of 70 may be unnecessary—and even harmful—for some women, a new study suggests.1 The research, published earlier this month in the Annals of Internal Medicine, raises questions about the risks of overdiagnosis and the efficacy of blanket recommendations that apply to all women in this age group. “A key message from our research is: There’s no one-size-fits-all solution for older women,” Ilana Richman, MD, MHS, an internal medicine specialist and assistant professor at Yale School of Medicine, and the first author of the new study, told Health.Source: Health
Study Shows Promise of Immunotherapy Treatment for Penile Cancer
An international study led by Yale Cancer Center researchers at Yale School of Medicine found that the use of immune checkpoint inhibitors offers promising clinical benefits for some patients with advanced penile squamous cell carcinoma.